Changes in levels of monocytes, T cells, and dendritic cell (DC) counts under tocilizumab treatment. Distinction was made between responders and nonresponders at Week 12. Each p value corresponds to the result of a Wilcoxon signed-rank test in each subgroup. Values are mean ± SD except where indicated.
| Phenotyping | Week 12 Responders, n = 25 | Week 12 Nonresponders, n = 6 | ||||
|---|---|---|---|---|---|---|
| Day 0 | Week 12 | p | Day 0 | Week 12 | p | |
| CD3+ total | 1304 ± 696 | 1335 ± 809 | 0.73 | 1054 ± 692 | 774 ± 458 | 0.11 |
| CD3+CD4+ cells | 880 ± 467 | 900 ± 551 | 0.77 | 754 ± 550 | 511 ± 295 | 0.11 |
| CD3+CD8+ cells | 368 ± 244 | 378 ± 261 | 0.77 | 243 ± 140 | 208 ± 146 | 0.24 |
| Monocytes (range) | 550 (490–760) | 474 (370–615) | 7.10−3 | 400 (215–603) | 402 (270–555) | 0.62 |
| Myeloid DC | 10,342 ± 7747 | 6430 ± 4159 | 0.03 | 3256 ± 5642 | 2368 ± 847 | 0.71 |
| Plasmacytoid DC | 6011 ± 4110 | 6438 ± 4505 | 0.61 | 2390 ± 4223 | 2767 ± 1472 | 0.71 |